Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 2;5(5):e2213643.
doi: 10.1001/jamanetworkopen.2022.13643.

Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation

Affiliations

Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation

Tapio Paljarvi et al. JAMA Netw Open. .

Abstract

Importance: The evidence base for the association between montelukast and adverse neuropsychiatric outcomes is mixed and inconclusive. Several methodological limitations have been identified in the evidence base on the safety of montelukast in observational studies.

Objective: To investigate the association between new montelukast exposure and 1-year incident neuropsychiatric diagnoses with improved precision and control for baseline confounders.

Design, setting, and participants: This propensity score-matched cohort study was conducted using electronic health records from 2015 to 2019 in the TriNetX Analytics Network patient repository of more than 51 million patients from 56 health care organizations, mainly in the US. Included patients were those aged 15 to 64 years at index prescription for montelukast or for control prescription who had a history of asthma or allergic rhinitis. After propensity score matching for various baseline confounders, including comorbidities and dispensed prescription medicines, we included 154 946 patients, of whom 77 473 individuals were exposed to montelukast. Patients were followed up for 12 months. Data were analyzed from June through November 2021.

Exposures: New dispensed prescription for leukotriene receptor antagonist montelukast or control medication.

Main outcomes and measures: Incident neuropsychiatric diagnoses at 12 months identified using International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes.

Results: There were 72 490 patients with asthma (44 726 [61.7%] women; mean [SD] age at index prescription, 35 [15] years) and 82 456 patients with allergic rhinitis (54 172 [65.7%] women; mean [SD] age at index prescription, 40 [14] years). In patients exposed to montelukast, the odds ratio [OR] for any incident neuropsychiatric outcome was 1.11 (95% CI, 1.04-1.19) in patients with asthma and 1.07 (95% CI, 1.01-1.14) in patients with allergic rhinitis compared with patients who were unexposed. The highest OR was for anxiety disorders (OR, 1.21; 95% CI, 1.05-1.20) among patients with asthma exposed to montelukast and insomnia (OR, 1.15; 95% CI, 1.05-1.27) among patients with allergic rhinitis exposed to montelukast.

Conclusions and relevance: This study found that patients with asthma or allergic rhinitis had increased odds of adverse neuropsychiatric outcomes after montelukast initiation. These findings suggest that clinicians should consider monitoring potential adverse mental health symptoms during montelukast treatment, particularly in individuals with a history of mental health or sleep problems.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Luciano reported being an employee of TriNetX, which provided data for this study, outside the submitted work. No other disclosures were reported.

Similar articles

Cited by

References

    1. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med. 2005;99(4):444-450. doi:10.1016/j.rmed.2004.09.008 - DOI - PubMed
    1. Ji T, Lu T, Qiu Y, et al. . The efficacy and safety of montelukast in children with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med. 2021;78:193-201. doi:10.1016/j.sleep.2020.11.009 - DOI - PubMed
    1. Rozin SI. Case series using montelukast in patients with memory loss and dementia. Open Neurol J. 2017;11(11):7-10. doi:10.2174/1874205X01711010007 - DOI - PMC - PubMed
    1. Hoxha M, Rovati GE, Cavanillas AB. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol. 2017;73(7):799-809. doi:10.1007/s00228-017-2242-2 - DOI - PubMed
    1. Rahman SO, Singh RK, Hussain S, Akhtar M, Najmi AK. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer’s disease. Eur J Pharmacol. 2019;842(842):208-220. doi:10.1016/j.ejphar.2018.10.040 - DOI - PubMed

Publication types